#USA #Denver #QuantiPath #GenoPATHx #Jeff Nauseda

QuantiPath Appoints Jeff Nauseda as Director of Market Development

In a significant move to bolster its market position, QuantiPath, a prominent player in genomic pathogen diagnostics for food safety, has announced the recruitment of Jeff Nauseda as their new Director of Market Development. This strategic appointment is set against the backdrop of the upcoming launch of QuantiPath's groundbreaking platform, GenoPATHX, which is tailored to enhance pathogen detection in the beef and pet food sectors.

Jeff Nauseda: A Veteran in Food Safety

Jeff Nauseda brings over 22 years of extensive experience in strategic business development and the food safety domain. His track record includes successful stints at leading firms like SGS, bioMérieux, and Abbott Laboratories, where he exhibited a knack for forging commercial partnerships and aligning cutting-edge technical solutions with customer requirements. His expertise will be instrumental as QuantiPath aims to significantly expand its footprint in the burgeoning beef and pet food markets.

As Director of Market Development, Nauseda will spearhead initiatives to cater to these high-growth segments, emphasizing the critical need for precise and reliable pathogen testing. This role will see him collaborating closely with QuantiPath's technical, regulatory, and sales teams to customize the GenoPATHX platform according to the unique pathogen and regulatory demands specific to beef and pet food producers and their processing laboratories.

Strategic Integration into the Livestock Industry

John LoPorto, President and CEO of QuantiPath, emphasized the importance of Nauseda's appointment at this juncture, describing it as a pivotal step for the company. He remarked, "His domain expertise in commercializing rapid methods for foodborne pathogen detection, combined with his strategic relationships, will accelerate our entry into the beef and pet food markets." With Nauseda on board, QuantiPath can now present a comprehensive diagnostic suite for the livestock and protein sectors, extending its leadership capabilities beyond its established focus on poultry and swine.

QuantiPath's flagship offering, the GenoPATHX platform, represents a state-of-the-art solution for pathogen detection. It is a deep-serotyping qPCR assay that can identify and quantify multiple Salmonella serovars in a single test without requiring sample enrichment. This innovative technology aims to provide same-day actionable results, thereby granting food processors and laboratories essential insights into potential product and environmental contamination levels.

The GenoPATHX suite will also introduce offerings focused on STEC (Shiga toxin–producing E. coli), Listeria, and Campylobacter, with a staggered rollout planned for 2026. QuantiPath's recent rebranding from Food Supply Security reflects its broader mission of enhancing pathogen quantification and diagnostic accuracy across the food supply chain.

Future Prospects in Genomic Diagnostics

With a dedicated Vice President for poultry, two directors spearheading initiatives in livestock, and an adept science and operations team poised to support cross-species deployment, QuantiPath has laid a robust foundation for its future endeavors. Nauseda's role complements this vision, fortifying the company's readiness as it prepares for the comprehensive market introduction of GenoPATHX. The burgeoning demand for genomic diagnostics in food safety positions QuantiPath favorably in a landscape increasingly attentive to pathogen detection in various protein sources.

As QuantiPath prepares to unfurl the GenoPATHX platform, the strategic appointment of Jeff Nauseda marks a significant milestone in its journey, epitomizing its commitment to leading the charge in enhancing food safety through precision genetic diagnostics and fostering trust and confidence in food safety from farm to table.

To learn more about QuantiPath and its innovative solutions, visit QuantiPath.bio.